Primary Objective: To describe the immune response induced by VRVg-2 and Verorab vaccines at D14 and D35 when co-administered with Human Rabies Immunoglobulins (HRIG) at D0, according to the Zagreb (2-1-1) IM regimen in healthy adult subjects. Secondary Objective: Immunogenicity To describe the immune response induced by VRVg-2 and Verorab vaccines at D90 when co-administered with HRIG at D0, according to the Zagreb (2-1-1) IM regimen in healthy adult subjects. Safety To describe the safety profile of VRVg-2 and Verorab vaccines when co administered with HRIG at D0, after each vaccination.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of participants achieving rabies virus neutralizing antibody (RVNA) titer greater than or equal to (≥) 0.5 IU/mL
Timeframe: Day 14 (post-vaccination)
Percentage of participants achieving RVNA titer greater than or equal to (≥) 0.5 IU/mL
Timeframe: Day 35 (post-vaccination)
Number of Participants achieving RVNA titer greater than or equal to (≥) lower limit of quantification
Timeframe: Day 14 (post-vaccination)
Number of Participants achieving RVNA titer greater than or equal to (≥) lower limit of quantification
Timeframe: Day 35 (post-vaccination)
Geometric Mean Titer Ratio (GMTR) of individual RVNA titer: (post-/pre-vaccination)
Timeframe: Day 14 (post-vaccination
Geometric Mean Titer Ratio (GMTR) of individual RVNA titer: (post-/pre-vaccination)
Timeframe: Day 35 (post-vaccination)